Cory Renauer: While most promising young biotechs devote all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy of aiming for the middle. Its plan for developing biosimilars
By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little
Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ) Q2 2014 Results Earnings Conference Call July 31 ..... gentlemen, and thank you for standing by. Welcome to the Momenta Pharmaceuticals ’ Second Quarter 2014 Earnings Call. At this time
Momenta Pharmaceuticals ( MNTA -3.5% ) Q2 results : Collaboration revenue: $11.0M (+151.1%); Operating Expenses: $37.3M (+11.3%); Operating
Momenta Pharmaceuticals (NASDAQ: MNTA ): Q2 EPS of -$0.51 misses by $0.07 . Revenue of $10.95M (+151.1% Y/Y) misses by $0.27M . Press Release Post your comment!
GTLS , H , HGG , HL , HP , HST , IDA , IMN , INCY , IRDM , IRM , ITT , IVZ , K , KMT , LKQ , LLL , LM , MA , MCK , MD , MDP , MNTA , MOD , MOS , MPC , MPLX , MSCI , MTOR , MWIV , NGD , NI , NJR , NWL , OAK , OCN , ODFL , OXY , PCG , PCRX , PES , PNR , PNW
Increasing pharmaceutical complexity shines light on Momenta's capabilities.
Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic
We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million
We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U